Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.

Abstract

Mechanism-based inhibition of CYP2B6 in human liver microsomes by thienopyridine antiplatelet agents ticlopidine and clopidogrel and the thiolactone metabolites of those two agents plus that of prasugrel were investigated by determining the time- and concentration-dependent inhibition of the activity of bupropion hydroxylase as the typical CYP2B6 activity. By comparing the ratios of k(inact) (maximal inactivation rate constant)/K(I) (the inactivator concentration producing a half-maximal rate of inactivation), it was found that the thiolactone metabolite of prasugrel is 10- and 22-fold less potent, respectively, in the mechanism-based inhibition of CYP2B6 than ticlopidine and clopidogrel. The k(inact)/K(I) ratio of the thiolactone metabolite of ticlopidine was comparable with that of the parent compound, whereas this ratio for the thiolactone metabolite of clopidogrel was significantly smaller than that of clopidogrel. In conclusion, ticlopidine, its thiolactone metabolite, and clopidogrel were more potent mechanism-based inhibitors of CYP2B6 than the thiolactone metabolite of prasugrel.

DOI: 10.1124/dmd.108.022988

2 Figures and Tables

Statistics

010020020102011201220132014201520162017
Citations per Year

300 Citations

Semantic Scholar estimates that this publication has 300 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nishiya2009MechanismbasedIO, title={Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.}, author={Yumi Nishiya and Katsunobu Hagihara and Takashi Ito and Masami Tajima and Shin-ichi Miura and Atsushi Kurihara and Nagy A Farid and Toshihiko Ikeda}, journal={Drug metabolism and disposition: the biological fate of chemicals}, year={2009}, volume={37 3}, pages={589-93} }